Skip to main navigation
Cue Logo
Skip to Content
Cue Logo
  • Overview
  • News & Events
    • News Releases
    • Events and Presentations
  • Corporate Governance
    • Governance Overview
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
  • Stock Information
    • Stock Quote
    • Analyst Coverage
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact Investor Relations

News
Releases

Date Title
Jan 11, 2022
Cue Health Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
Jan 06, 2022
Cue Health to Develop Omicron-Genotyping COVID-19 Test in Partnership with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA)
Jan 05, 2022
Cue Health to Present at the 40th Annual J.P. Morgan Healthcare Conference

Shareholder Tools

Print Page Print Page
Email Alerts Email Alerts
RSS RSS
Contact Contact

This website contains depictions of contemplated future products and future care offerings that are still under development by Cue Health and that have not received regulatory authorization, clearance or approval. Currently, the only products authorized for commercial sale in the United States are Cue Health’s COVID-19 tests, which are currently commercially available in the United States pursuant to two Emergency Use Authorizations from the U.S. Food & Drug Administration.

  • © 2022 Cue Health Inc. All rights reserved. Cue and the Cue logo are registered trademarks of Cue Health Inc.